Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

124.12 +1.02 (+0.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio? ↗
10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them. 
Via Benzinga
News headline image
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review ↗
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
News headline image
Why Neurocrine Biosciences Stock Was Tumbling This Week ↗
The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea. 
Via The Motley Fool
News headline image
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
NASDAQ:NBIX is not too expensive for the growth it is showing. ↗
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock ↗
Neurocrine Biosciences reports positive Phase 2 trial results for NBI-1117568 in adults with schizophrenia, showing significant reduction in PANSS scores with a 20 mg dose. Piper Sandler upgrades the... 
Via Benzinga
News headline image
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results ↗
 
Via Benzinga
News headline image
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors ↗
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. 
Via Benzinga
News headline image
US Stocks Mixed; JM Smucker Slashes Annual Guidance ↗
 
Via Benzinga
News headline image
A Closer Look at 7 Analyst Recommendations For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
NASDAQ:NBIX, a strong growth stock, setting up for a breakout. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
News headline image
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers ↗
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. 
Via Investor's Business Daily
News headline image
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna ↗
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
News headline image
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). ↗
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) suited for quality investing? 
Via Chartmill
News headline image
9 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
So Much For Expecting The Fed To Stick The Landing ↗
Now is not the time to be fully invested. 
Via Talk Markets
Topics Economy
News headline image
NASDAQ:NBIX, a growth stock which is not overvalued. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
News headline image
Should Quality Investors Include NASDAQ:NBIX in Their Portfolio? ↗
Why Quality Investors May Find NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Attractive. 
Via Chartmill
News headline image
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review ↗
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
NASDAQ:NBIX is not too expensive for the growth it is showing. ↗
Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Reasonable Growth, Debt Levels, and a High ROIC Make NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Appealing to Quality Investors. ↗
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a quality stock. 
Via Chartmill
News headline image
Despite its impressive fundamentals, NASDAQ:NBIX remains undervalued. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline ↗
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
Via InvestorPlace
News headline image
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? ↗
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans ↗
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
News headline image
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. ↗
Investors should take note ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a growth stock that remains attractively priced. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.